Clinical trial
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in…
NCT03733990 · Faron Pharmaceuticals Ltd, Industry · Completed
Key facts
| NCT number | NCT03733990 |
|---|---|
| Title | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) |
| Official title | A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours |
| Lead sponsor | Faron Pharmaceuticals Ltd, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Biological |
| Interventions | FP-1305 (bexmarilimab) |
| Enrollment | 216 |
| Start date | Dec 3, 2018 |
| Primary completion | Sep 6, 2023 |
| Completion | Oct 31, 2023 |
| First posted | Nov 7, 2018 |
| Last update posted | Apr 2, 2025 |
| Countries | Finland, France, Netherlands, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: